Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients

Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients

Head and neck squamous cell carcinoma (HNSCC) patients treated with high-dose cisplatin concurrently with radiotherapy (hdCis-RT) commonly suffer kidney injury leading to acute and chronic kidney disease (AKD and CKD, respectively). We conducted a retrospective analysis of renal function and kidney...

Full description

Bibliographic Details
Main Authors: K.A. Mapuskar, G. Vasquez Martinez, C.F. Pulliam, M.S. Petronek, E.J. Steinbach, V. Monga, M. Furqan, J.G. Jetton, D.P. Saunders, A. Pearce, S. Davidson, L. Pitre, N.E. Dunlap, R. Fairbanks, C.M. Lee, S.L. Mott, K.L. Bodeker, Huang Cl, J.M. Buatti, C.M. Anderson, R.A. Beardsley, J.T. Holmlund, D. Zepeda-Orozco, D.R. Spitz, B.G. Allen
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Redox Biology
Subjects:
Superoxide dismutase mimetic
Avasopasem manganese
GC4419
Cisplatin
Radiation
Kidney injury
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231722003718

Internet

http://www.sciencedirect.com/science/article/pii/S2213231722003718

Similar Items